Complete Responses in the TEMPI Syndrome After Treatment With Daratumumab

N Engl J Med. 2018 Jun 7;378(23):2240-2242. doi: 10.1056/NEJMc1804415.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Paraproteinemias / drug therapy*
  • Polycythemia / drug therapy*
  • Syndrome
  • Telangiectasis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • daratumumab